Risk factors
Neumora Therapeutics (NMRA) risk factors
Item 1A of every Neumora Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors91 risks7 new2 dropped12 reworded
Accumulated deficit reached $1,184.1 million as clinical-stage development continues without approved products. The company addressed Nasdaq minimum bid price compliance issues in 2025. Exposure to the enacted BIOSECURE Act threatens foreign manufacturing and vendor relationships.
Filed Mar 30, 2026 - FY2024 10-K risk factors86 risks
Neumora faces substantial clinical and regulatory risks as a clinical-stage biopharmaceutical company focused on the historically challenging neuroscience field.
Filed Mar 03, 2025